M2e, human, a vaccine candidate for human influenza A, encompasses the 23 extracellular residues of M2 (the third integral membrane protein of influenza A) and exhibits remarkable conservation across all strains, highlighting its potential as a broadly protective option.
Onilcamotide, a cancer vaccine derived from the C-terminal peptide of the RhoC protein, exhibits potential immunomodulating and antineoplastic activities.
STh, also known as Escherichia coli heat-stable toxin, is a 19 amino acid polypeptide containing three disulfide bridges. It serves as an antigen of significance in the quest for a comprehensive enterotoxigenic Escherichia coli (ETEC) vaccine.
KRAS G13D peptide, a 25-mer sequence, is derived from the KRAS activating oncogene mutation and serves as an immune potentiator. This peptide possesses immunogenic properties and can be utilized for the development of a KRAS vaccine.